search

Active clinical trials for "Dermatitis, Atopic"

Results 81-90 of 1075

A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD)...

Atopic Dermatitis

The co-primary objectives of the study are to: Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD). Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Eczema Area and Severity Index (EASI).

Recruiting17 enrollment criteria

Induced Pluripotent Stem Cell Derived Exosomes for the Treatment of Atopic Dermatitis

Atopic Dermatitis

Evaluate the safety, tolerability, and preliminary efficacy of GD-iExo-001 in the treatment of atopic dermatitis

Recruiting27 enrollment criteria

A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

This phase II clinical trials is multicenter, randomized, double-blind, placebo-controlled to assess the effectiveness and safety of TQH2722 injection in the treatment of subjects with moderate to severe atopic dermatitis.

Recruiting46 enrollment criteria

Comparison of LimpiAD Cream 2.5% Plus Versus Its Vehicle and and a Basic Emollient in Patients With...

Atopic Dermatitis

The purpose of this clinical trial is to assess the efficacy and tolerability of LimpiAD, a medical device in the formulation of a 2.5% Plus cream, versus the Vehicle of LimpiAD 2,5% Plus cream, and versus a basic emollient in subjects with mild to moderate Atopic Dermatitis.

Recruiting19 enrollment criteria

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic...

Atopic DermatitisModerate-to-severe Atopic Dermatitis1 more

The primary objective of this study is to evaluate the safety of IMG-007 in adults with moderate-to-severe AD. The secondary objectives are to evaluate the pharmacokinetics and efficacy of IMG-007 in AD patients.

Recruiting12 enrollment criteria

Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)

Atopic DermatitisSkin Diseases

This study investigates 3 different doses of orismilast modified release compared to placebo in adult patients with moderate-to-severe atopic dermatitis. The purpose of the study is to assess the effect of orismilast modified release in moderate-to-severe atopic dermatitis and assess the safety aspects of these 3 different doses. The patients will receive an oral treatment of either orismilast modified release tablets or placebo tablets 2 times a day for 16 weeks.

Recruiting11 enrollment criteria

A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe...

Atopic Dermatitis

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.

Recruiting27 enrollment criteria

An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

Atopic Dermatitis

Phase 2 study of RPT193 in adults with atopic dermatitis

Recruiting17 enrollment criteria

Clinical Trial to Evaluate the Effect of a Probiotic Mixture in the Treatment of Atopic Dermatitis...

Atopic Dermatitis

A prospective case-control multicentric pilot study of 12 weeks duration to evaluate the effect of a probiotic mixture in the treatment of atopic dermatitis in children from 0 to 3 years old, by measuring the severity of the condition using the SCORAD index, as well as the Clinical Global Impression rating scale, the potential decrease in the use of corticosteroids and antihistamines, and the safety of the treatment under study by the number of adverse events related to the product under study.

Recruiting16 enrollment criteria

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

Atopic Dermatitis

This is a multi-center, longitudinal study which will characterize the gene expression profiles and transcriptomic endotypes that underlie mild and moderate-severe Atopic dermatitis (AD) and will determine changes in these expression patterns and endotypes in response to standard-of-care treatment. Participants will complete up to ten study visits with assessment of topical steroid response and dupilumab response (if uncontrolled with topical steroids). Skin samples will be collected at all study visits to determine the gene expression profiles and transcriptomic endotypes that underlie mild vs. moderate-severe AD disease. The investigators will also evaluate the lipidomic, metabolomic, proteomic, and microbiome profiles of AD skin endotypes associated with mild and moderate-severe AD disease. Non-AD participants will serve as a control population. The primary objective of this study is to determine if the type 2-high non-lesional skin (skin tape) endotype is associated with current mild versus moderate-severe AD disease.

Recruiting45 enrollment criteria
1...8910...108

Need Help? Contact our team!


We'll reach out to this number within 24 hrs